Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk (NVO) stock extended gains on Friday after the pharmaceutical giant announced a partnership with Amazon Pharmacy for its FDA-approved oral weight-loss pill. 

According to its press release, Amazon Pharmacy will offer access to oral Wegovy at competitive price points starting at $25 for insured patients and $149 for uninsured customers. 

Fundamentals

See More
  • Market Capitalization, $K 1,005,472,640
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.35
  • Price/Sales 16.12
  • Price/Cash Flow 76.24
  • Price/Book 43.01

Options Overview Details

View History
  • Implied Volatility 40.40% (-0.05%)
  • Historical Volatility 27.14%
  • IV Percentile 76%
  • IV Rank 38.66%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Expected Move (DTE 4) 35.19 (3.31%)
  • Put/Call Vol Ratio 0.86
  • Today's Volume 46,810
  • Volume Avg (30-Day) 43,569
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 400,895
  • Open Int (30-Day) 403,942
  • Expected Range 1,028.37 to 1,098.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.47
  • Number of Estimates 7
  • High Estimate 8.72
  • Low Estimate 7.00
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +40.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
977.12 +8.85%
on 12/10/25
1,133.95 -6.21%
on 01/08/26
+81.34 (+8.28%)
since 12/09/25
3-Month
783.85 +35.68%
on 10/17/25
1,133.95 -6.21%
on 01/08/26
+208.21 (+24.34%)
since 10/09/25
52-Week
623.78 +70.50%
on 08/08/25
1,133.95 -6.21%
on 01/08/26
+276.34 (+35.10%)
since 01/08/25

Most Recent Stories

More News
Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here?

Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.

NVO : 58.81 (+2.56%)
LLY : 1,063.56 (-1.99%)
Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

NEW YORK and NEW ORLEANS , Jan. 8, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC ("KSF") are investigating the...

VTYX : 13.81 (-0.22%)
LLY : 1,063.56 (-1.99%)
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and Zepbound...

LLY : 1,063.56 (-1.99%)
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

VTYX : 13.81 (-0.22%)
LLY : 1,063.56 (-1.99%)
Eli Lilly (LLY) Stock Is Up, What You Need To Know

Eli Lilly (LLY) Stock Is Up, What You Need To Know

LLY : 1,063.56 (-1.99%)
2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore

2 Cash-Producing Stocks to Keep an Eye On and 1 We Ignore

LLY : 1,063.56 (-1.99%)
MSCI : 581.16 (-0.03%)
UBER : 85.44 (-2.45%)
Stocks Finish Higher on Strength in Chip Makers and Energy Producers

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.64%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.77%. March E-mini S&P...

MSTR : 157.33 (-5.77%)
MPC : 176.17 (-0.51%)
HL : 22.45 (+6.85%)
CDE : 20.40 (+3.98%)
ADI : 300.93 (+0.59%)
GLXY : 24.94 (-2.20%)
JNJ : 204.39 (-0.66%)
SLB : 45.20 (+1.73%)
QXO : 25.00 (+1.42%)
AMGN : 326.10 (-1.21%)
COIN : 240.78 (-1.96%)
PNR : 103.06 (unch)
Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

JNJ : 204.39 (-0.66%)
LLY : 1,063.56 (-1.99%)
ABBV : 220.08 (-1.81%)
GSK : 50.39 (+0.34%)
CSLLY : 58.5300 (-0.43%)
PFE : 25.48 (+0.75%)
SNY : 49.03 (+1.87%)
These 3 Stocks Trade at Discounts the Market Won’t Ignore Forever

With the S&P 500 trading at 26 times forward earnings, valuations are a concern entering 2026. Consider these 3 discounted stocks to insulate your portfolio.

NVDA : 184.86 (-0.10%)
GOOGL : 328.57 (+0.96%)
CMCSA : 28.37 (+0.57%)
T : 23.99 (-0.74%)
MU : 345.09 (+5.53%)
LLY : 1,063.56 (-1.99%)
PFE : 25.48 (+0.75%)
DIS : 115.88 (+1.50%)
2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm

2 Unpopular Stocks That Deserve Some Love and 1 That Underwhelm

DIN : 36.23 (-1.74%)
LLY : 1,063.56 (-1.99%)
ANF : 124.87 (-3.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,132.53
2nd Resistance Point 1,118.53
1st Resistance Point 1,091.04
Last Price 1,063.56
1st Support Level 1,049.55
2nd Support Level 1,035.55
3rd Support Level 1,008.06

See More

52-Week High 1,133.95
Last Price 1,063.56
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar